Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2027-06-15
Target enrollment:
Participant gender:
Summary
n the present study the neoadjuvant approach with the anti-HER2 trastuzumab and pertuzumab
combined with carboplatin and paclitaxel will be used to compare the Event-Free Survival
(EFS) in regimens with and without atezolizumab. Following the neoadjuvant part of the study,
after surgery all patients will continue to receive trastuzumab and pertuzumab to complete
one year of anti-HER2 therapy. Similarly, patients allocated to receive atezolizumab will
continue atezolizumab to complete one year In addition, several IHC and molecular assays will
be performed before and during the period of chemotherapy administration and at surgery with
the goal of defining a marker of efficacy to be later validated in a larger adjuvant setting.